Fig. 4

a: CT scan after treatment with an RNA oligonucleotide drug, MTL-CEBPA. b: CT scan showing smaller lesions in March 2018 after treatment with Sorafenib. c: CT scan showing continued response 8 weeks after sorafenib was stopped